vs

Side-by-side financial comparison of First Northwest Bancorp (FNWB) and RECURSION PHARMACEUTICALS, INC. (RXRX). Click either name above to swap in a different company.

RECURSION PHARMACEUTICALS, INC. is the larger business by last-quarter revenue ($35.5M vs $18.4M, roughly 1.9× First Northwest Bancorp). First Northwest Bancorp runs the higher net margin — 2.6% vs -304.2%, a 306.8% gap on every dollar of revenue. On growth, RECURSION PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (681.7% vs 19.1%). Over the past eight quarters, RECURSION PHARMACEUTICALS, INC.'s revenue compounded faster (60.5% CAGR vs 6.8%).

First Midwest Bancorp, Inc. was headquartered in Chicago, Illinois, just east of O'Hare Airport. The company's predecessor traces back to Joliet, Illinois. From there the company has grown to serve many Chicago suburbs including northwest Indiana, downstate Illinois, southeast Wisconsin and the Quad Cities area including Iowa. First Midwest Bank is one of the largest banking institutions in the United States

Recursion Pharmaceuticals is a clinical-stage biotechnology company that combines artificial intelligence and large-scale high-throughput biological experimentation to discover and develop innovative therapies for rare diseases, oncology, inflammatory disorders, and other areas of unmet medical need. It primarily operates in North America and partners with global biopharmaceutical firms to advance its robust therapeutic pipeline.

FNWB vs RXRX — Head-to-Head

Bigger by revenue
RXRX
RXRX
1.9× larger
RXRX
$35.5M
$18.4M
FNWB
Growing faster (revenue YoY)
RXRX
RXRX
+662.7% gap
RXRX
681.7%
19.1%
FNWB
Higher net margin
FNWB
FNWB
306.8% more per $
FNWB
2.6%
-304.2%
RXRX
Faster 2-yr revenue CAGR
RXRX
RXRX
Annualised
RXRX
60.5%
6.8%
FNWB

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
FNWB
FNWB
RXRX
RXRX
Revenue
$18.4M
$35.5M
Net Profit
$382.0K
$-108.1M
Gross Margin
59.8%
Operating Margin
6.2%
-304.8%
Net Margin
2.6%
-304.2%
Revenue YoY
19.1%
681.7%
Net Profit YoY
113.6%
39.6%
EPS (diluted)
$0.04
$-0.17

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
FNWB
FNWB
RXRX
RXRX
Q4 25
$18.4M
$35.5M
Q3 25
$16.6M
$5.2M
Q2 25
$16.4M
$19.2M
Q1 25
$17.6M
$14.7M
Q4 24
$15.4M
$4.5M
Q3 24
$15.8M
$26.1M
Q2 24
$21.6M
$14.4M
Q1 24
$16.1M
$13.8M
Net Profit
FNWB
FNWB
RXRX
RXRX
Q4 25
$382.0K
$-108.1M
Q3 25
$802.0K
$-162.3M
Q2 25
$3.7M
$-171.9M
Q1 25
$-9.0M
$-202.5M
Q4 24
$-2.8M
$-178.9M
Q3 24
$-2.0M
$-95.8M
Q2 24
$-2.2M
$-97.5M
Q1 24
$396.0K
$-91.4M
Gross Margin
FNWB
FNWB
RXRX
RXRX
Q4 25
59.8%
Q3 25
-183.8%
Q2 25
-4.9%
Q1 25
-48.0%
Q4 24
-181.4%
Q3 24
53.7%
Q2 24
36.2%
Q1 24
19.1%
Operating Margin
FNWB
FNWB
RXRX
RXRX
Q4 25
6.2%
-304.8%
Q3 25
-0.9%
-3327.6%
Q2 25
24.2%
-916.8%
Q1 25
-57.7%
-1297.9%
Q4 24
-17.3%
-4042.4%
Q3 24
-20.1%
-377.1%
Q2 24
-12.8%
-697.4%
Q1 24
5.2%
-698.4%
Net Margin
FNWB
FNWB
RXRX
RXRX
Q4 25
2.6%
-304.2%
Q3 25
4.8%
-3135.3%
Q2 25
22.4%
-894.2%
Q1 25
-51.3%
-1373.3%
Q4 24
-19.9%
-3935.5%
Q3 24
-12.5%
-367.5%
Q2 24
-10.3%
-676.6%
Q1 24
2.5%
-662.4%
EPS (diluted)
FNWB
FNWB
RXRX
RXRX
Q4 25
$0.04
$-0.17
Q3 25
$0.09
$-0.36
Q2 25
$0.42
$-0.41
Q1 25
$-1.03
$-0.50
Q4 24
$-0.31
$-0.56
Q3 24
$-0.23
$-0.34
Q2 24
$-0.25
$-0.40
Q1 24
$0.04
$-0.39

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
FNWB
FNWB
RXRX
RXRX
Cash + ST InvestmentsLiquidity on hand
$743.3M
Total DebtLower is stronger
$9.6M
Stockholders' EquityBook value
$157.3M
$1.1B
Total Assets
$2.1B
$1.5B
Debt / EquityLower = less leverage
0.01×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
FNWB
FNWB
RXRX
RXRX
Q4 25
$743.3M
Q3 25
$659.8M
Q2 25
$525.1M
Q1 25
$500.5M
Q4 24
$594.4M
Q3 24
$427.6M
Q2 24
$474.3M
Q1 24
$296.3M
Total Debt
FNWB
FNWB
RXRX
RXRX
Q4 25
$9.6M
Q3 25
$11.9M
Q2 25
$14.2M
Q1 25
$16.4M
Q4 24
$19.0M
Q3 24
$20.5M
Q2 24
$22.9M
Q1 24
Stockholders' Equity
FNWB
FNWB
RXRX
RXRX
Q4 25
$157.3M
$1.1B
Q3 25
$154.5M
$1.0B
Q2 25
$149.7M
$919.1M
Q1 25
$146.5M
$933.9M
Q4 24
$153.9M
$1.0B
Q3 24
$160.8M
$524.6M
Q2 24
$158.9M
$584.4M
Q1 24
$160.5M
$401.2M
Total Assets
FNWB
FNWB
RXRX
RXRX
Q4 25
$2.1B
$1.5B
Q3 25
$2.1B
$1.4B
Q2 25
$2.2B
$1.3B
Q1 25
$2.2B
$1.3B
Q4 24
$2.2B
$1.4B
Q3 24
$2.3B
$726.5M
Q2 24
$2.2B
$775.9M
Q1 24
$2.2B
$557.8M
Debt / Equity
FNWB
FNWB
RXRX
RXRX
Q4 25
0.01×
Q3 25
0.01×
Q2 25
0.02×
Q1 25
0.02×
Q4 24
0.02×
Q3 24
0.04×
Q2 24
0.04×
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
FNWB
FNWB
RXRX
RXRX
Operating Cash FlowLast quarter
$-2.8M
$-46.1M
Free Cash FlowOCF − Capex
$-47.3M
FCF MarginFCF / Revenue
-133.1%
Capex IntensityCapex / Revenue
3.5%
Cash ConversionOCF / Net Profit
-7.22×
TTM Free Cash FlowTrailing 4 quarters
$-378.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
FNWB
FNWB
RXRX
RXRX
Q4 25
$-2.8M
$-46.1M
Q3 25
$4.7M
$-117.4M
Q2 25
$4.0M
$-76.4M
Q1 25
$-21.7M
$-132.0M
Q4 24
$16.9M
$-115.4M
Q3 24
$1.2M
$-59.2M
Q2 24
$8.1M
$-82.2M
Q1 24
$-4.9M
$-102.3M
Free Cash Flow
FNWB
FNWB
RXRX
RXRX
Q4 25
$-47.3M
Q3 25
$-117.6M
Q2 25
$-79.6M
Q1 25
$-133.8M
Q4 24
$-116.7M
Q3 24
$-63.8M
Q2 24
$-83.4M
Q1 24
$-5.0M
$-109.0M
FCF Margin
FNWB
FNWB
RXRX
RXRX
Q4 25
-133.1%
Q3 25
-2272.5%
Q2 25
-413.9%
Q1 25
-907.4%
Q4 24
-2567.7%
Q3 24
-244.6%
Q2 24
-578.5%
Q1 24
-30.9%
-789.9%
Capex Intensity
FNWB
FNWB
RXRX
RXRX
Q4 25
3.5%
Q3 25
4.7%
Q2 25
16.4%
Q1 25
12.4%
Q4 24
28.6%
Q3 24
17.5%
Q2 24
8.2%
Q1 24
0.7%
48.2%
Cash Conversion
FNWB
FNWB
RXRX
RXRX
Q4 25
-7.22×
Q3 25
5.89×
Q2 25
1.08×
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
-12.29×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons